Association of C3435T Single-Nucleotide Polymorphism of <i>MDR1</i> Gene with Breast Cancer in an Iranian Population

Tatari, Farnoosh; Salek, Roham; Mosaffa, Fatemeh; Khedri, Azam; Behravan, Javad

doi:10.1089/dna.2008.0826

Cited by 30 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, no significant difference was found when genotypes were analyzed in relation to the clinical-pathological features in the IDBC group (Table 3). Clinical-pathological formation can result in several cancer types (Trock et al, 1997;Tatari et al, 2009;Rao et al, 2010;Sabahi et al, 2010;Mhaidat et al, 2011). Several studies have investigated the association of the C3435T polymorphism with breast cancer development, prognosis, and treatment outcome; however, the inconsistent and contradicting evidence has led to a confused picture (Turgut et al, 2007;Huang et al, 2008;Rodrigues et al, 2008;George et al, 2009;Taheri et al, 2010;Chen et al, 2012).…”

Section: Resultsmentioning

confidence: 99%

MDR1 C3435T polymorphism in Mexican patients with breast cancer

et al. 2014

View full text Add to dashboard Cite

ABSTRACT. We investigated whether the MDR1 C3435T polymorphism is associated with fibrocystic changes (FCC), infiltrating ductal breast cancer (IDBC), and/or clinical-pathological features of IDBC in Mexican patients. Samples from women who received surgical treatment in 2007 at the Centro Médico de Occidente (México) were included in the analysis. Genotyping was performed by polymerase chain reaction-restricted fragment length polymorphisms in 64 paraffin-embedded breast samples with IDBC, 64 samples with FCC, and 183 peripheral blood samples of healthy females designated as the healthy group (HG). The frequency of the T allele was 41, 45, and 52% for the FCC, IDBC, and HG samples, respectively. Significant differences were only found between the FCC The prevalence of the T/T genotype was 8, 13, and 24% for FCC, IDBC, and HG samples, respectively. Again, statistical differences were only found between FCC and HG samples for the T/T genotype (OR = 0.28, 95%CI = 0.106-0.77; P = 0.009). Although the T allele and the T/T genotype were less frequent in the IDBC group than in the HG, the differences were not significant. Furthermore, no associations were found between the C3435T polymorphism and clinical-pathological features of the IDBC group. Both the FCC and IDBC groups had a high frequency of the C allele relative to the HG in this sample of women from Western Mexico.

show abstract

Section: Resultsmentioning

confidence: 99%

MDR1 C3435T polymorphism in Mexican patients with breast cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…14,[18][19][20][24][25][26] Several studies have considered the relationship between MDR1 expression and C3435T polymorphism examining clinical and pathological characteristics in patients with breast cancer. 11,22,23 However, the correlation was either nonsignificant or there was insufficient data. A significant association between patients with DIC and lobular invasive carcinoma was observed (T vs C: P ¼ 0.024) in the group we tested.…”

Section: Discussionmentioning

confidence: 98%

“…Our results were gained in contrast to work carried out by other researchers, who observed no significant differences in genotype and allele frequencies between Iranian patients with breast cancer and control subjects (P ¼ 0.744 and 0.590, respectively). 23 Furthermore, the C3435T genotype-related disease risk has been studied in several other cancers (renal cell carcinoma, colon cancer, lung cancer, acute lymphoblastic and myeloid leukemia, glioma) with mixed and inconsistent results. 14,[18][19][20][24][25][26] Several studies have considered the relationship between MDR1 expression and C3435T polymorphism examining clinical and pathological characteristics in patients with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome

et al. 2009

View full text Add to dashboard Cite

P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome. We examined the relevance of C3435T polymorphism in relation to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, the therapeutic response and hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, stage and histological grade was observed (P ¼ 0.024, 0.014, 0.006, respectively, w 2 -test or Fisher's exact test). We also found significantly higher (P ¼ 0.019, w 2 -test) T allele frequency in breast cancer patients (n ¼ 221) than in controls (n ¼ 113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n ¼ 38; P ¼ 0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n ¼ 102; P ¼ 0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable.

show abstract

“…1 There are several reports which showed no significant differences between C3435T MDR1 gene polymorphisms and other diseases, In the study done by Tatari et al, it was shown there were no significant differences in genotypes and allele frequencies between patients with breast cancer and control subjects in an Iranian population. 13 Kim et al suggested C3435T polymorphism in the multidrug-resistant epilepsy may not be significant in Korean populations. 14 However, the association of C3435TMDR1 gene polymorphism with incidence of different diseases is yet controversial.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of C3435T <i>MDR1</i> Gene Polymorphism in Adult Patient with Acute Lymphoblastic Leukemia

et al. 2011

View full text Add to dashboard Cite

Background: P-glycoprotein (P-gp) is a transmembrane pump encoded by MDR1 gene. It contributes in protection of the cells against xenobiotic and toxic compounds. P-gp also contributes in multidrug resistance in acute lymphoblastic leukemia (ALL). Human MDR1 polymorphism include C to T exchange at position 3435, individuals with TT polymorphism have lower expression of P-gp than the others with CC genotypes. Accumulation of xenobiotics in the cells can cause some diseases like cancers.Materials and Methods: To evaluate MDR1C3435T gene polymorphism in adult patients with ALL, 54 patients and 96 healthy controls were involved in our survey. Genotyping of ALL patients and healthy controls was performed by Polymerase Chain Reaction – Restriction Fragment- Length Polymorphism (PCR-RFLP). Data analysis was done by SPSS software through T-test and Chi- Square. Results: No significant difference was found between C3435T MDR1 gene polymorphisms and incidence of ALL in adult patients. Also there was not any significant difference between T and C alleles and incidence of ALL. Conclusion: C3435T MDR1 polymorphism is not associated with the incidence of ALL in the population studied. Keyword: P-gp; C3435T; MDR1; ALL; polymorphism DOI: 10.3329/jom.v12i1.5541J Medicine 2011; 12 : 3-6

show abstract

Association of C3435T Single-Nucleotide Polymorphism of MDR1 Gene with Breast Cancer in an Iranian Population

Cited by 30 publications

References 22 publications

MDR1 C3435T polymorphism in Mexican patients with breast cancer

MDR1 C3435T polymorphism in Mexican patients with breast cancer

MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome

Evaluation of C3435T <i>MDR1</i> Gene Polymorphism in Adult Patient with Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About